Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

IMPORTANCE: Although highly effective disease-modifying therapies for multiple sclerosis (MS) have been associated with an increased risk of infections vs injectable therapies interferon beta and glatiramer acetate (GA), the magnitude of potential risk increase is not well established in real-world...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Archives of neurology (Chicago) 2020-02, Vol.77 (2), p.184-191
Hauptverfasser:	Luna, Gustavo, Alping, Peter, Burman, Joachim, Fink, Katharina, Fogdell-Hahn, Anna, Gunnarsson, Martin, Hillert, Jan, Langer-Gould, Annette, Lycke, Jan, Nilsson, Petra, Salzer, Jonatan, Svenningsson, Anders, Vrethem, Magnus, Olsson, Tomas, Piehl, Fredrik, Frisell, Thomas
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibiotics Antiviral agents Clinical Medicine Comments Copolymer 1 Data collection Design modifications Female Fingolimod Hydrochloride - therapeutic use Health risks Humans Immunosuppressive Agents - therapeutic use Immunotherapy Incidence Infections Infections - epidemiology Infections - etiology Interferon Klinisk medicin Male Medical and Health Sciences Medical treatment Medicin och hälsovetenskap Middle Aged Monoclonal antibodies Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - complications Multiple Sclerosis, Relapsing-Remitting - drug therapy Natalizumab - therapeutic use Neurologi Neurology Online First Original Investigation Patients Public health Registries Risk assessment Rituximab Rituximab - therapeutic use Sweden - epidemiology World population
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!